An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
U.S. Patent Office Re-Institutes Post Grant Review of Seagen Patent in Dispute between Daiichi Sankyo and Seagen
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Daiichi Sankyo Co., Ltd. (TSE: 4568) announced that the U.S. Patent and Trademark Office has granted its request to reinstitute post-grant review of the patentability of Seagen’s U.S. patent 10,808,039. Corporate Officer Naoto Tsukaguchi expressed satisfaction with the PTO’s decision, citing compelling evidence of the patent's unpatentability. This review follows a petition filed by Daiichi Sankyo on December 23, 2020, and previous actions by the PTO, including a rehearing request by Seagen. The result of this review could significantly impact Daiichi Sankyo's competitive position in the oncology sector.
Positive
U.S. PTO granted request to reinstitute post-grant review of patent, indicating potential weakening of Seagen's patent position.
Negative
None.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--
Daiichi Sankyo Co., Ltd. (TSE: 4568) (hereinafter, Daiichi Sankyo) announced today that the U.S. Patent and Trademark Office (PTO) granted its request to re-institute post-grant review (PGR) of the patentability of certain claims of Seagen’s U.S. patent 10,808,039 (the ’039 patent).
“We are very pleased that the PGR will be reinstituted given the PTO’s determination that our petition presented compelling evidence of unpatentability of the ’039 patent,” said Naoto Tsukaguchi, Corporate Officer and General Counsel, Daiichi Sankyo, Co., Ltd.
On December 23, 2020, Daiichi Sankyo filed a petition with the U.S. PTO for post-grant review contesting the patentability of certain claims of the ’039 patent. On April 7, 2022, the U.S. PTO initiated post-grant review of the ’039 patent to determine whether the claims of that patent should not have originally been granted. On July 15, 2022, the U.S. PTO granted Seagen’s request for rehearing of the decision to institute post-grant review, deciding not to proceed with the PGR process. On February 7, 2023, a PTO Precedential Opinion Panel issued an order instructing the original PGR panel to decide whether the PGR should be reinstituted by applying the applicable standard of whether Daiichi Sankyo’s petition presented compelling evidence of unpatentability.
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit: www.daiichisankyo.com.
